Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Total Non-Current Liabilities (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Total Non-Current Liabilities for 13 consecutive years, with $188.5 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 98.63% to $188.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $188.5 million through Dec 2025, up 98.63% year-over-year, with the annual reading at $188.5 million for FY2025, 98.63% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $188.5 million at Theravance Biopharma, up from $182.5 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $746.3 million in Q1 2021, with the low at $89.5 million in Q4 2023.
  • Average Total Non-Current Liabilities over 5 years is $323.0 million, with a median of $179.4 million recorded in 2025.
  • The sharpest move saw Total Non-Current Liabilities crashed 85.96% in 2022, then surged 98.63% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $638.4 million in 2021, then plummeted by 85.96% to $89.6 million in 2022, then fell by 0.07% to $89.5 million in 2023, then grew by 6.01% to $94.9 million in 2024, then surged by 98.63% to $188.5 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $188.5 million, $182.5 million, and $199.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.